Ross River virus evolution: Implications for vaccine development

Future Virology

Volumn 7, Issue 2, 2012, Pages 173-178

  Aaskov, John ^a   Fokine, Andrei ^b   Liu, Wenjun ^c  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b PURDUE UNIVERSITY   (United States)

^c AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

Author keywords

genetic diversity; neutralization; Ross River virus; vaccine

Indexed keywords

ALUMINUM HYDROXIDE; VIRUS VACCINE;

ANTIGENIC VARIATION; GENETIC VARIABILITY; HEALTH PROGRAM; HUMAN; MOSQUITO; NONHUMAN; PRIORITY JOURNAL; REVIEW; ROSS RIVER ALPHA VIRUS; TOGAVIRUS INFECTION; VIRUS ISOLATION;

ALPHAVIRUS; ROSS RIVER VIRUS;

EID: 84863168197     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.139     Document Type: Review

References (41)

1. Fraser JRE. Epidemic polyarthritis and Ross River virus disease. Clin. Rheum. Dis. 12(2), 369-388 (1986). (Pubitemid 16027735)
2. Doherty RL, Carley JG, Best JC. Isolation of Ross River virus from man. Med. J. Aust. 1(21), 1083-1084 (1972).
3. Harley D, Sleigh A, Ritchie S. Ross River virus transmission, infection and disease: a cross-disciplinary review. Clin. Microbiol. Rev. 14(4), 909-932 (2001). (Pubitemid 32979635)
4. Aaskov JG, Ross P, Davies CEA et al. Epidemic polyarthritis in northeastern Australia, 1978-1979. Med. J. Aust. 2(1), 17-19 (1981). (Pubitemid 11011506)
5. Kistner O, Barrett N, Bruhmann A et al. The pre-clinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans. Vaccine 25(25), 4845-4852 (2007). (Pubitemid 46818611)
6. Staikowsky F, Talarmin F, Grivard P et al. Prospective study of Chikungunya virus acute infection in the island of La Reunion during the 2005-2006 outbreak. PLoS One 4(10), E7603 (2009).
7. Aaskov JG, Mataika JU, Lawrence GW et al. An epidemic of Ross River virus infection in Fiji, 1979. Am. J. Trop. Med. Hyg. 30(5), 1053-1059 (1981).
8. Klapsing P, MacLean JD, Glaze S et al. Ross River virus disease re-emergence, Fiji, 2003-2004. Emerg. Infect. Dis. 11(4), 613-615 (2005). (Pubitemid 40462914)
9. Nimmo JR. An unusual epidemic. Med. J. Aust. 1, 549-550 (1928).
10. Shope RE, Anderson SG. The virus aetiology of epidemic exanthem and polyarthritis. Med. J. Aust. 47(1), 156-158 (1960).
11. Doherty RL, Whitehead RH, Gorman BM, O'Gower AK. The isolation of a third group A arbovirus in Australia, with preliminary observations on its relationship to epidemic polyarthritis. Aust. J. Sci. 26(6), 183-184 (1963).
12. Aaskov JG, Ross PV, Harper JJ, Donaldson MD. Isolation of Ross River virus fromepidemic polyarthritis patients in Australia. Aust. J. Exp. Biol. Med. Sci. 63(5), 587-597 (1985). (Pubitemid 16175280)
13. Wiemers MA, Stallman ND. Immunoglobulin M in Murray Valley encephalitis. Pathology 7(3), 187-191 (1975).
14. Oseni RA, Donaldson MD, Dalglish DA, Aaskov JG. Detection by ELISA of IgM antibodies to Ross River virus in serum from patients with suspected epidemic polyarthritis. Bull. World Health Organ. 61(4), 703-708 (1983). (Pubitemid 13010189)
15. Aaskov JG, Chen JY, Hanh NT, Dennington PM. Surveillance for Ross River virus infection using blood donors. Am. J. Trop. Med. Hyg. 58(6), 726-730 (1998). (Pubitemid 28307388)
16. Russell RC. Ross River virus: ecology and distribution. Ann. Rev. Entomol. 47, 1-31 (2002). (Pubitemid 34108574)
17. Kitchen LW, Vaughn DW. Role of the U.S. military in the development of U.S.-licensed vaccines for naturally occurring infectious diseases. Vaccine 25(41), 7017-7030 (2007). (Pubitemid 47470095)
18. Griffin DE. Alphaviruses. In: Fields Virology (5th Edition). Knipe DM (Ed.). Lippincott Williams and Wilkins, PA, USA, 1023-1068 (2007).
19. Randall R, Mills JW, Engell LL. The preparation and properties of a purified equine encephalomyelitis vaccine. J. Immunol. 55(1), 41-52 (1947).
20. Smith DG, Mamay HK, Marshall RG, Wagner JC. Venezulean equine encephalomyelitis. Laboratory aspects of fourteen human cases following vaccination and attempts to isolate the virus from the vaccine. Am. J. Hyg. 63(2), 150-164 (1956).
21. Weaver SC, Pfeffer M, Marriott K, Kang W, Kinney R. Genetic evidence for the origins of Venezulean equine encephalitis virus sub-type IAB outbreaks. Am. J. Trop. Med. Hyg. 60(3), 441-448 (1999). (Pubitemid 29162128)
22. Nathanson N, Langmuir AD. The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. II. Relationship of poliomyelitis to the Cutter vaccine. Am. J. Hyg. 78, 29-60 (1963).
23. Engler RJM, Mangisfico JA, Jahrling P, Ksiazek TG, Pedrotti-Krueger M, Peters CJ. Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine. J. Med. Virol. 38(4), 305-310 (1992). (Pubitemid 23000560)
24. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiological study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89(4), 405-421 (1969).
25. Yu S, Aaskov JG. Development of a candidate vaccine against Ross River virus infection. Vaccine 12(12), 1118-1124 (1994). (Pubitemid 24267361)
26. Aaskov JG, Williams L, Yu S. A candidate Ross River virus vaccine: preclinical evaluation. Vaccine 15(12), 1396-1404 (1997). (Pubitemid 27397820)
27. Holzer GW, Coulibaly S, Aichinger G et al. Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunisation models and establishment of a correlate of protection. Vaccine 29(24), 4132-4141 (2011).
28. Aichinger G, Ehrlich HJ, Aaskov JG et al. Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomised trial. Vaccine 29, 9376-9384 (2011).
29. Strauss JH, Strauss EG. The alphaviruses: gene expression, replication and evolution. Microbiol. Rev. 58(3), 491-562 (1994).
30. Strizki JM, Repik PM. Differential reactivity of immune sera from human vaccinees with field strains of eastern equine encephalitis virus. Am. J. Trop. Med. Hyg. 53(5), 564-570 (1995).
31. Sammels LM, Coelen RJ, Lindsay MD, Mackenzie JS. Geographic distribution and evolution of Ross River virus in Australia and the Pacific islands. Virology 212(1), 20-29 (1995).
32. Jones A, Lowry K, Aaskov J, Holmes EC, Kitchen A. Molecular evolutionary dynamics of Ross River virus and implications for vaccine efficacy. J. Gen. Virol. 91(1), 182-188 (2010).
33. Steinhauer DA, Domingo E, Holland JJ. Lack of evidence for proofreading mechanisms associated with an RNA polymerase. Gene 122(2), 281-288 (1992). (Pubitemid 23030332)
34. Liu WJ, Rourke MF, Holmes EC, Aaskov JG. Persistence of multiple genetic lineages within intrahost populations of Ross River virus. J. Virol. 85(11), 5674-5678 (2011).
35. Woodroofe G, Marshall ID, Taylor WP. Antigenically distinct strains of Ross River virus from north Queensland and coastal New South Wales. Aust. J. Exp. Biol. Med. Sci. 55(1), 79-87 (1977). (Pubitemid 8124166)
36. Vrati S, Fernon CA, Dalgarno L, Weir RC. Location of a major antigenic site involved in Ross River virus neutralization. Virology 162(2), 346-353 (1988). (Pubitemid 18068919)
37. Smith TJ, Cheng RH, Olson NH et al. Putative receptor binding sites on alphaviruses as visualised by cryoelectron microscopy. Proc. Natl Acad. Sci. USA 92(23), 10648-10652 (1995).
38. Houghten RA. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc. Natl Acad. Sci. USA 82(15), 5131-5135 (1985). (Pubitemid 16242814)
39. Blondel B, Crainic R, Fichet O et al. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 polio virus can be located outside or inside the antibody binding site. J. Virol. 57(1), 81-90 (1986). (Pubitemid 16147920)
40. Porterfield JS. Antibody-dependent enhancement of viral infectivity. Adv. Virus Res. 31, 335-355 (1986).
41. Linn ML, Aaskov JG, Suhrbier A. Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis. J. Gen. Virol. 77(3), 407-411 (1996). (Pubitemid 26073343)